



File 454

Circular 19/05

**Pharmaceutical Service**

**Prescribing List Changes**

This circular is to remind colleagues that the Prescribing and Formulary Panel recommended that all strengths and presentations of the following products be removed from the Prescribing List on May 1<sup>st</sup> 2019.

1. Liothyronine
2. Alimemazine
3. Trimipramine

You will be aware that these products have been subject to excessive price inflation by the manufacturers and that there are numerous better value and equally effective alternatives available for patients. All of the changes have the support of the relevant local specialists, who can be contacted for advice on individual patients if difficulties arise. Messages have been on Scriptswitch for some time.

**Doctors** : please note the above and ensure that no more repeat prescriptions are issued for these products.

**Pharmacists** : Kindly note the above for discussions with patients. Please do not dispense prescriptions for any of these products after May 1st 2019 as they will be disallowed.

Thank you in advance for your kind co-operation with this matter. As always please do not hesitate to get in touch if there are any queries or concerns about this circular.

**Geraldine O’Riordan**  
**Prescribing Advisor**  
**April 11<sup>th</sup> 2019**